CTRI/2024/02/062959招募中3 期
ow Level vs Intermittent Stimulation of Peroxisome Proliferator Activated Receptor Gamma on Insulin resistance and its effect on Glycemic Control - LIYASAI
Dr Deepak Anand R0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •HbA1C more than 7.0 %
- •FBS more than 126 mg/dl
- •RBS more than 200 mg/dl
- •Any duration of Diabetes Mellitus
- •On oral antidiabetics or naive to medications
- •BMI between 18 and 35 kg/cm
排除标准
- •On insulin treatment or be
- •initiated during study period
- •Patients on pioglitazone or have received pioglitazone in the last one year
- •Past H/O Hematuria
- •Liver enzymes more than 2.5 ULN at
- •eGFR less than 60mg/dl
- •Concomitant CAD and/or Heart
- •Pedal edema of any cause
- •On Digoxin, Warfarin, Oral
- •Contraceptives
- •Females of childbearing potential
- •Pregnant females & Nursing
- •Presence of proliferative diabetic
- •retinopathy
- •Patients who have not given
研究者
相似试验
进行中（未招募）
不适用
Effects of the activation of PPARs in the orphan hepatic disease primary biliary cirrhosisp to 67% of PBC patients have an incomplete biochemical response to UDCA and remain at increased risk for progression to cirrhosis and liver-related death. In this study we will prospectively examine the therapeutic effects of bezafibrate (a pan-agonist activating PPARalpha/delta/gamma) in patients with early-stage PBC with a specific focus on improvement of liver functions, inflammation, lipid profile, oxidative status and endothelial function.EUCTR2011-004681-15-ATMedizinische Universität Graz
已完成
不适用
Can the use of the Peroxisome Proliferator-Activated Receptor (PPAR)-gamma agonist rosiglitazone reverse the abnormal distribution of fat, as well as disturbances in glucose and lipid metabolism in Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndrome?Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndromeInfections and InfestationsHuman Immunodeficiency VirusISRCTN78808170Academic Medical Centre (AMC) (The Netherlands)15
进行中（未招募）
不适用
The effect of peroxisome proliferator activator receptor ? agonist pre-treatment on pegylated interferon-a2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial - - HEPAR studyChronic hepatitis C infectionMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2007-007075-16-NLVU university medical center50
撤回
不适用
The effect of peroxisome proliferator activator receptor * agonist pre-treatment on pegylated interferon-*2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trialViral liver disease1001965410047438Hepatitis CNL-OMON31787Vrije Universiteit Medisch Centrum50
进行中（未招募）
1 期
The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer - PPAREUCTR2006-001398-44-GBBarts and The London NHS Trust49